Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Navamedic ASA is a Nordic pharmaceutical company headquartered in Oslo, Norway, specializing in the supply of high-quality prescription drugs, consumer health products, and medical nutrition to hospitals and pharmacies. Incorporated in 2002 and listed on the Oslo Stock Exchange since 2006, it addresses key public health challenges such as obesity, Parkinson’s disease, antibiotics, addiction treatment, metabolism, cardiology, urology, and women’s health. The company operates across the Nordic countries—Norway, Sweden, Denmark, and Finland—as well as the Benelux region, Baltics, UK, and Greece, with a team of approximately 42 professionals. Navamedic’s portfolio includes Rx and OTC pharmaceuticals, medical devices, food supplements, and cosmetics, sourced via strategic distribution agreements and in-licensing deals. Notable developments include the 2025 acquisition of the dne pharma business to strengthen addiction treatment and innovations in personalized Parkinson’s dosing solutions. Achieving sales of 531 million NOK in 2024, Navamedic serves as a vital partner for international firms seeking market access in Northern Europe through its regulatory expertise and local insights.
NOK 1.42
+NOK 0.00 (+0.00%)
EOD Jul 1, 2026
Operating margin is thin at 2.88%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 6.4%, steady but not accelerating. Margins contracted 3.1pp, which offsets some of the top-line progress.
Free cash flow declined 36% versus the prior year, cash generation momentum has weakened. ROIC dropped from 6.83% to 2.80%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 565M
▲ +6.4% YoY
Net Income (TTM)
-NOK 24M
▼ -329.1% YoY
Op. Margin
2.88%
▼ -3.1pp YoY
ROIC
2.80%
▼ -4.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
NOK 23M
▼ -35.6% YoY
Op. Cash Flow (TTM)
NOK 26M
▼ -35.0% YoY
Net Debt
NOK 145M
Cash & Equiv.
NOK 82M
3Y CAGR: +13.9%
3Y CAGR: +13.9%
Continue Research
Navamedic ASA (NAVA.XOSL) trades below a two-stage DCF intrinsic value of about NOK 29.59 per share, so at NOK 1.42 the stock looks undervalued (1,991.5% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Navamedic ASA scores 48/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about NOK 29.59 per share for NAVA.XOSL, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around NOK 22.20. At today's NOK 1.42, that puts the stock about 1,991.5% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Navamedic ASA scores 48 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 2.9% operating margin and a 2.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. NAVA.XOSL currently trades below its estimated intrinsic value and scores 48/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.